physostigmine

Physostigmine is an alkaloid extracted from the poison bean (Physostigma venenosum) and acts as a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine inhibits the action of acetylcholinesterase, increasing acetylcholine levels, and thus serves as an antidote for anticholinergic poisoning. Physostigmine crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine can reverse memory deficits in transgenic mice with Alzheimer's disease.

Physostigmine, a parasympathomimetic alkaloid, is a reversible cholinesterase inhibitor. It extracts from the Calabar bean.

cholinesterase inhibitor

Neostigmine bromide is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.

Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.

Phenserine is a derivative of Physostigmine and is annoncompetitive, long-acting and selective inhibitor of AChE.

Biperiden Hydrochloride (KL 373 Hydrochloride) is an anticholinergic antiparkinsonian agent that selectively blocks central M1 cholinoreceptors while exerting atropine-like effects on peripheral parasympathetic structures. Biperiden Hydrochloride is approved for the adjunctive treatment of postencephalitic, idiopathic, and arteriosclerotic Parkinson’s disease, demonstrates minimal impairment of novelty preference compared with other anticholinergics in comparative cognitive studies, and is associated with known adverse effects including drowsiness, vertigo, headache, and dizziness.

Eseroline is a potent μ-opioid receptor agonist and a hydrolytic metabolite of Physostigmine. It serves as a selective and competitive acetylcholinesterase (AChE) inhibitor, with inhibition constants (Ki) of 0.1 μM for AChE and 200 μM for butyrylcholinesterase (BuChE). Eseroline acts as an allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL), enhancing Ach-induced nAChR signaling without directly activating the receptor. The compound is neurotoxic, causing cellular membrane damage (LDH leakage) and energy metabolism collapse (ATP depletion). Additionally, Eseroline can be utilized in Alzheimer's disease research.

Neostigmine hydroxide is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.

Cymserine is a drug related to physostigmine, which acts as a reversible cholinesterase inhibitor, with moderate selectivity for the plasma cholinesterase enzyme butyrylcholinesterase, and relatively weaker inhibition of the better-known acetylcholinesterase enzyme.

(-)-Eseroline fumarate, a metabolite of the acetylcholinesterase inhibitor Physostigmine, promotes lactic acid dehydrogenase (LDH) leakage from cancer cells and triggers adenine nucleotides and 5-hydroxytryptamine (5-HT) release from neuronal cells, leading to cell death. Additionally, it suppresses electrically evoked muscle contractions in the mouse vas deferens and the guinea-pig ileum.

Phenserine tartrate ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine and functions as an efficient, non-competitive, long-acting, and selective inhibitor of acetylcholinesterase (AChE). This compound reduces the formation of amyloid precursor protein (APP) and β-amyloid peptides (Aβ), potentially improving cognitive abilities and alleviating the progression of Alzheimers disease.